Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glucagon-like peptides

D J Drucker1

  • 1Department of Medicine, the Toronto Hospital, Banting and Best Diabetes Centre, University of Toronto, Ontario, Canada. d.drucker@utoronto.ca

Diabetes
|March 31, 1998
PubMed
Summary
This summary is machine-generated.

Glucagon-like peptides (GLP-1 and GLP-2) from the intestine show therapeutic potential for diabetes and intestinal diseases. GLP-1 regulates blood glucose and appetite, while GLP-2 promotes intestinal growth.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intra-islet glucagon signalling regulates beta-cell connectivity, first-phase insulin secretion and glucose homoeostasis.

Molecular metabolism·2024
Same author

Glucagon-like peptide 1 (GLP-1).

Molecular metabolism·2019
Same author

Regulation of glucose kinetics during exercise by the glucagon-like peptide-1 receptor.

The Journal of physiology·2012
Same author

Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology.

Diabetologia·2011
Same author

Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice.

Diabetologia·2010
Same author

Smoking habits in hospital.

Canadian Medical Association journal·2010
Same journal

Ketone Bodies Derived From Medium-Chain Triglycerides Support Brain Metabolism and Function Under Hypoglycemia in Type 1 Diabetes Mellitus.

Diabetes·2026
Same journal

Targeting the ADA/ADO Axis Rescues β-Cell Failure in Type 2 Diabetes.

Diabetes·2026
Same journal

TXNIP Is Positioned as a Key Mediator of Hyperglycemia-Induced Vascular Senescence.

Diabetes·2026
Same journal

Sex Differences in ER Stress Pathways Are a Key Determinant of β-Cell Proliferation and Resilience.

Diabetes·2026
Same journal

The Mechanism of TNF-α Combined With High Glucose in Regulating Calnexin Aggravates Endoplasmic Reticulum Stress in Endothelial Cell Injury of Diabetic Retinopathy.

Diabetes·2026
Same journal

β-Hydroxybutyrate Improves Glucose Metabolism in Streptozotocin-Induced Type 1 Diabetes by Inhibiting Gut and Liver Glucose Transporters via GPR109A.

Diabetes·2026
See all related articles

Area of Science:

  • Endocrinology
  • Gastroenterology
  • Metabolic Research

Background:

  • Proglucagon yields glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) from intestinal enteroendocrine cells.
  • GLP-1 is crucial for glucose homeostasis, impacting insulin secretion, gastric emptying, and glucagon levels.
  • GLP-1 also influences appetite regulation and peripheral metabolic processes, with its short duration linked to DPP-IV degradation.

Purpose of the Study:

  • To review recent advancements in understanding the biological activities of GLP-1 and GLP-2.
  • To explore the therapeutic potential of GLP-1 for diabetes mellitus (both NIDDM and IDDM).
  • To investigate the emerging role of GLP-2 in intestinal health and regeneration.

Main Methods:

  • Literature review of recent scientific publications on glucagon-like peptides.

Related Experiment Videos

  • Analysis of studies detailing the physiological effects of GLP-1 and GLP-2 in vitro and in vivo.
  • Examination of clinical data regarding the therapeutic applications of GLP-1 and GLP-2 analogs.

    • Main Results:

    • GLP-1 effectively lowers blood glucose in diabetic patients through multiple mechanisms.
    • GLP-1 demonstrates significant effects on food intake and body weight regulation in preclinical models.
    • GLP-2 exhibits intestinal growth factor activity, suggesting potential for treating intestinal disorders.

    Conclusions:

    • GLP-1 holds considerable therapeutic promise for managing diabetes mellitus.
    • GLP-2 presents a novel therapeutic avenue for promoting mucosal regeneration in gastrointestinal diseases.
    • Further research into DPP-IV resistant analogs and GLP-2 mechanisms could enhance clinical utility.